| Autor: |
Violeta Salceda-Rivera, Isidoro Tejocote-Romero, Diana S. Osorio, Rosalba Bellido-Magaña, Araceli López-Facundo, Susana E. Anaya-Aguirre, Daniel Ortiz-Morales, Roberto Rivera-Luna, Evelyne Reyes-Gutiérrez, Rebeca Rivera-Gómez, Liliana Velasco-Hidalgo, Deyanira Cortés-Alva, Sandra Lagarda-Arrechea, Farina E. Arreguín-González, Alma E. Benito-Reséndiz, Silvia Chávez-Gallegos, Eloy Pérez-Rivera, Guillermo J. Gaytán-Fernández, José A. León-Espitia, Jociela Domínguez-Sánchez, Carlos Leal-Cavazos, Citlalli Simón-González, Tania C. Larios-Farak, Nubia A. Macías-García, Ana C. García-Espinosa, Francisco Guerrero-Maymes, Paola Casillas-Toral, Oscar González-Ramella |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 14 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2024.1376574 |
| Popis: |
IntroductionData on medulloblastoma outcomes and experiences in low- and middle-income countries, especially in Latin America, is limited. This study examines challenges in Mexico’s healthcare system, focusing on assessing outcomes for children with medulloblastoma in a tertiary care setting.MethodsA retrospective analysis was conducted, involving 284 patients treated at 21 pediatric oncology centers in Mexico.ResultsHigh-risk patients exhibited markedly lower event-free survival than standard-risk patients (43.5% vs. 78.3%, p1.5cm², and lower radiotherapy doses significantly impacted event-free survival (EFS) and overall survival (OS). Platinum-based chemotherapy showed better results compared to the ICE protocol in terms of OS and EFS, which was associated with higher toxicity. Patients under 3 years old displayed notably lower OS and EFS compared to older children (36.1% vs. 55.9%, p=0.01). |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
